METHODS: Consecutive patients with clinical and radiographic evidence of CMC OA were treated with DN. The primary outcome measure was pain using the Numerical Pain Rating Scale (NPRS) at 12 weeks. Secondary outcome measures were the Upper Extremity Functional Index (UEFI-20) and the Global Rating of Change (GROC) scale. Outcome measures were collected at baseline, 4 weeks, 8 weeks, and 12 weeks.
RESULTS: Nine patients were treated for six sessions of periosteal DN over 3 weeks. Compared to baseline, statistically significant and clinically meaningful improvements were observed in thumb pain (NPRS mean difference: 2.6; p = 0.029) and function (UEFI-20 mean difference: 21.3; p = 0.012) at 12 weeks.
CONCLUSIONS: Statistically significant and clinically meaningful within-group improvements in thumb pain and function were observed at 12 weeks following six sessions of periosteal DN treatment. DN may be a useful intervention in the management of patients with CMC OA of the thumb.
方法:连续有临床和影像学证据的CMCOA患者接受DN治疗。主要结果测量是在12周时使用数值疼痛评定量表(NPRS)的疼痛。次要结果指标是上肢功能指数(UEFI-20)和全球变化评分(GROC)量表。结果指标是在基线时收集的,4周,8周,和12周。
结果:9例患者在3周内接受了6次骨膜DN治疗。与基线相比,12周时拇指疼痛(NPRS平均差异:2.6;p=0.029)和功能(UEFI-20平均差异:21.3;p=0.012)均有统计学意义和临床意义的改善.
结论:在6次骨膜DN治疗后12周时,观察到拇指疼痛和功能的组内有统计学意义和临床意义的改善。DN可能是管理拇指CMCOA患者的有用干预措施。